Published in final edited form as:

Adv Synth Catal. 2011 June 30; 353(10): 1729–1734. doi:10.1002/adsc.201000835.

Organocatalytic High Enantioselective Synthesis of β -Formyl- α -hydroxyphosphonates

Sandun Perera^a, Vijaya Kumar Naganaboina^a, Long Wang^b, Bin Zhang^{*,b}, Qunsheng Guo^a, Laxmidhar Rout^a, and Cong-Gui Zhao^{a,*}

^aDepartment of Chemistry, University of Texas at San Antonio, One UTSA Circle, San Antonio, TX 78249, USA

^bDepartment of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, Texas, 78229-3900, USA

Abstract

The cross aldol reaction between enolizable aldehydes and α -ketophosphonates was achieved for the first time by using 9-amino-9-deoxy-*epi*-quinine as the catalyst. β -Formyl- α -hydroxyphosphonates were obtained in high to excellent enantioselectivities. The reaction works especially well with acetaldehyde, which is a tough substrate for organocatalyzed cross aldol reactions. The products were demonstrated to have anticancer activities.

Keywords

ketophosphonate; aldehyde; primary amine; organocatalysis; hydroxyphosphonate

α -Hydroxyphosphonate derivatives are highly biologically active compounds.^[1] Previous studies have demonstrated that these compounds have anti-cancer,^[2] anti-virus,^[3] anti-bacterial^[4] and anti-fungal^[4] activities. They are also proven inhibitors of such important enzymes as renin^[5] and HIV (human immunodeficiency virus) protease and polymerase.^[6] Due to their relevance to biomedical applications, there have been considerable interests in developing highly enantioselective methods for the synthesis of these compounds in recent years.^[7-9] Our own interest^[8] in this area led to the development of an organocatalyzed asymmetric synthesis of α -hydroxyphosphonates on the basis a proline derivative-catalyzed cross aldol reaction.^[8a,b] Nevertheless, although high enantioselectivities have been achieved in the cross aldol reaction of ketones and α -ketophosphonates by others^[9] and us,^[8a,b] the cross aldol reaction of enolizable aldehydes and α -ketophosphonates proves to

*Tel: (+)-210-562-5234; zhangb3@uthscsa.edu . *Tel: (+1)-210-458-5432; Fax: (+1)-210-458-7428; cong.zhao@utsa.edu .

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/adsc.200#####>.

be very difficult.^[10] To our knowledge, such a reaction has not been realized so far. Herein we wish to report the first organocatalyzed cross aldol reaction of enolizable aldehydes and α -ketophosphonates for the high enantioselective synthesis of tertiary β -formyl- α -hydroxyphosphonates,^[11,12] using a quinine-derived primary amine as the catalyst and the preliminary biological study of these compounds.

Although L-proline and L-prolinamide (compounds **1** and **2**, Figure 2) are excellent catalysts for the cross aldol reaction of acetone and α -ketophosphonates,^[8a,b] they fail to catalyze the cross aldol reaction between propanal and α -ketophosphonates.^[10] After carefully comparing the proposed transition states ^[8b,e] of these two similar reactions (Figure 1), we believe the reaction failed in the case of propanal because of the unfavorable interactions between the enamine methyl group and the large phosphonate group in the transition state (Figure 1, right structure). Thus, we hypothesized that the reaction should proceed if such unfavorable interactions are alleviated.

One way to reduce the unfavorable interactions is to use acetaldehyde (**9a**) as the substrate,^[13] since, with **9a**, the methyl group in the proposed transition state (Figure 1) will be replaced with a much smaller hydrogen atom (as in the acetone case). Acetaldehyde (**9a**) and diethyl benzoylphosphonate (**10a**) were then adopted as the substrates to test our hypothesis, using proline (**1**) and prolinamide (**2**) as the catalysts (Figure 2). As shown by the results collected in Table 1, indeed, after reacting in CH₂Cl₂ at room temperature for a week, the desired aldol product **11a** may be obtained in reasonable yields (50% and 59% with L-proline and L-prolinamide, respectively, entries 1 and 2). Diphenylprolinol catalysts **3** and **4** are known to catalyze high enantioselective cross aldol reactions of acetaldehydes;^[13a,b,l] however, poorer results were obtained with these two catalysts (entries 3 and 4). Nevertheless, since acetaldehyde is a known tough substrate for organocatalyzed cross aldol reactions,^[13a,b,l] we were encouraged by these results even though the enantioselectivities obtained were impractical.

Another way to solve the aforementioned problem is to use a different catalyst, because the transition state is known to be dependent on the catalyst structure and the catalysis mechanism. In this regard, we were very interested in primary amine catalysts,^[14] since primary amines would lead to less crowded transition states.^[14a] Thus, we screened several primary amines as the catalyst for the cross aldol of **9a** and **10a** (**5-8**, Figure 2). The results are also collected in Table 1. Among these catalysts, L-phenylalanine (**5**) is not effective at all as no desired product could be obtained after the reaction (entry 5). Nonetheless, in the presence of benzoic acid as the cocatalyst, (*S,S*)-1,2-diphenyl-1,2-ethanediamine (**6**) gave the expected product **11a** in 49% yield and 6% ee (entry 6). Catalysts **7** and **8**, derived from quinidine, and quinine, respectively, have been used by List co-workers as the catalyst in an intramolecular aldol reaction;^[14a] however, to our knowledge, they have never been used in an intermolecular aldol reaction. When **7** was used as the catalyst with benzoic acid as the cocatalyst, the expected **11a** was obtained in 45% yield and 17% ee (entry 5). The ee value was improved to 57% ee when compound **8** was applied (entry 6). Since catalyst **8** leads to highest ee value of the product, it was selected for further optimizations. Firstly, several acid cocatalysts were screened, and it was found that aliphatic acids, such as acetic acid and propionic acid, led to improved ee values of the product (71% and 74%, respectively, entries 9 and 10); however, the yields of the product were lower. In contrast, stronger acids, such as trifluoroacetic acid and toluenesulfonic acid, are not effective (entries 11 and 12). Additional screening identified 4-methoxybenzoic acid as the best cocatalyst, as the highest ee value of 75% was obtained in a reasonable yield (46%, entry 13). Then the solvent effects were evaluated (entries 14-18), and toluene was identified as the best solvent for this reaction, because the product **11a** could be obtained in 53% yield with a high ee value of 91% with this solvent (entry 16). Further optimization of the reaction temperature revealed that an

improved yield of 75% of the desired product could be obtained at 0 °C, with also a slightly improved ee value of 93% (entry 17). The improved product yield at this temperature was probably due to reduced competing reactions. Further dropping the reaction temperature, however, leads to inferior reaction yield without improvement in the ee value (data not shown). It should be pointed out that the major enantiomer obtained with catalyst **8** is opposite that of the rest catalysts.

Next the scope of this reaction was evaluated with different α -ketophosphonate and aldehyde substrates. The results are presented in Table 2. As shown in Table 2, the size of the ester alkyl groups in the phosphonate has almost no influence on the enantioselectivity of this reaction, as similar ee values were obtained for the methyl, ethyl and isopropyl esters (entries 1-3). The same is true with the electronic nature of the substituents on the phenyl ring of the benzoylphosphonates: Excellent ee values were obtained for both electron-withdrawing and electron-donating substituents (entries 4-9).

Benzoylphosphonate with an *ortho*-chloro substituent is less reactive and the yield obtained was much lower (entry 10), which is most probably due to steric reasons. However, as shown in Table 2, the position of the substituent on the phenyl ring has almost no influence on the enantioselectivity (entries 5, 10-12). Propanal, which has failed with other catalysts, also participates in the reaction under these new conditions, and the reaction yielded the desired product in 44% yield as a diastereomeric mixture (dr 7:5), with ee values of 68% and 73% for the major and minor diastereomers, respectively (entry 13). The methyl and hydroxy groups in the major diastereomer was determined to be *anti* by NOE experiments.

The fact that all the products obtained in this study are liquid makes the direct determination of the absolute configuration of major enantiomer obtained in this reaction difficult. To determine the absolute configuration of the major enantiomer, compound **11f** was converted to its 2,4-dinitrophenylhydrazone derivative **12** (Figure 3), and its stereochemistry at the quaternary stereogenic center was successfully determined to be *R* by X-ray crystallography.¹⁶ Thus, the absolute configuration of compound **11f** was assigned as *R*. On the basis of these results, a tentative mechanism is proposed to account for the formation of the major enantiomer in this reaction (Figure 4). The attack of the enamine on the *si* face of the hydrogen-bound α -ketophosphonate gives the expected *R*-enantiomer.

It is well known that α -hydroxyphosphonate derivatives are biologically active molecules. However, the biological activities of β -formyl- α -hydroxyphosphonates are still unknown. To assess their biological activities, we conducted some preliminary biological assays of these compounds. Thus, human immortalized Foreskin Fibroblasts (HFF) and ovarian cancer cells (ID8) were first incubated for 24 h, then the screened compounds was added in the indicated amount and the cells were further incubated for another 48 h. Cell proliferation was assessed by MTT assay as described previously and the results are presented in Figure 5.¹⁵

As shown in Figure 5, β -formyl- α -hydroxyphosphonate derivatives, II-SP-72 (**11h**), I-VKN-81 (**11a**) and I-VKN-97 (**11f**), significantly inhibited the proliferation of immortalized cell line HFF and ovarian cancer cell line ID8 in a dose-dependent manner (from 1 to 100 μ M). In contrast, a similar α -hydroxyphosphonate derivative that does not contain an aldehyde group, I-ZCG-1 (Figure 6), displays only minor antiproliferative activity at a high concentration (100 μ M). Interestingly, I-VKN-97 preferentially inhibited ID8 cancer cells rather than HFF immortalized cells. Moreover, antiproliferative effects of II-SP-72, I-VKN-81 and I-VKN-97 on other human (SKOV3 and K562) and murine tumour cells (B16F10) were also observed (data not shown).

In summary, we have developed the first cross aldol reaction of enolizable aldehydes and α -ketophosphonates for the highly enantioselective synthesis of tertiary β -formyl- α -

hydroxyphosphonates. The reaction utilizes a quinine-derived primary amine as the catalyst, and excellent enantioselectivities were achieved for the cross aldol products of acetaldehyde, which is unprecedented for such primary amine catalysts. Preliminary screen of some of the β -formyl- α -hydroxyphosphonate products indicates the products can suppress the proliferation of human and murine tumour cells, while are mild against immortalized cells (HFF).

Experimental Section

Typical Procedure for the Aldol Reaction

To a stirred solution of *p*-methoxybenzoic acid (13.7 mg, 0.09 mmol, 30 mol %) and quinine-derived amine **8** (9.7 mg, 0.03 mmol, 10 mol %) in toluene (2.0 mL) were added the α -ketophosphonate (0.30 mmol) and the aldehyde (1.5 mmol) at 0 °C. After the completion of reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure to yield the crude product, which was purified by column chromatography over silica gel (7:3 ethyl acetate/hexane) to furnish the desired β -formyl- α -hydroxyphosphonate as a pure compound.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The generous financial support of this project from the NIH-NIGMS (Grant no. SC1GM082718) and the Welch Foundation (Grant No. AX-1593) is gratefully acknowledged. The authors also thank Dr. Sampak Samanta for performing some initial experiments. The authors also thank Dr. Sampak Samanta for performing some initial experiments, Dr. William Haskins and the RCM Proteomics Core (NIH G12 RR013646) at UTSA for assistance with HRMS analysis, and Dr. Arman Hadi for performing X-ray analysis of compound **11f**.

References

- [1]. For reviews, see: a) Kolodiazny OI. *Tetrahedron: Asymmetry*. 2005; 16:3295–3340. b) Stawinski J, Kraszewski A. *Acc. Chem. Res.* 2002; 35:952–960. [PubMed: 12437320]
- [2]. a) Peters ML, Leonard M, Licata AA. *Clev. Clin. J. Med.* 2001; 68:945–951. b) Lee MV, Fong EM, Singere FR, Guenette RS. *Cancer Res.* 2001; 61:2602–2608. [PubMed: 11289137] c) Leder BZ, Kronenberg HM. *Gastroenterology*. 2000; 119:866–869. [PubMed: 10982780]
- [3]. Snoeck R, Holy A, Dewolf-Peeters C, Van Den Oord J, De Clercq E, Andrei G. *Antimicrob. Agents Chemother.* 2002; 46:3356–3361. [PubMed: 12384336]
- [4]. Kategaonkara AH, Pokalwara RU, Sonara SS, Gwalib VU, Shingate BB, Shingare MS. *Eur. J. Med. Chem.* 2010; 45:1128–1132. [PubMed: 20036039]
- [5]. a) Tao M, Bihovsky R, Wells GJ, Mallamo JP. *J. Med. Chem.* 1998; 41:3912–3916. [PubMed: 9748367] b) Dellaria JF Jr, Maki RG, Stein HH, Cohen J, Whittern D, Marsh K, Hoffman DJ, Plattner JJ, Perun TJ. *J. Med. Chem.* 1990; 33:534–542. [PubMed: 2105396]
- [6]. Stowasser B, Budt K-H, Li J-Q, Peyman A, Ruppert D. *Tetrahedron Lett.* 1992; 33:6625–6628.
- [7]. a) Suyama K, Sakai Y, Matsumoto K, Saito B, Katsuki T. *Angew. Chem.* 2010; 122:809–811. *Angew. Chem. Int. Ed.* 2010; 49:797–799. b) Gondi VB, Hagihara K, Rawal VH. *Angew. Chem.* 2009; 121:790–793. *Angew. Chem. Int. Ed.* 2009; 48:776–779. c) Abell JP, Yamamoto H. *J. Am. Chem. Soc.* 2008; 130:10521–10523. [PubMed: 18642910] d) Huang J, Wang J, Chen X, Wen Y, Liu X, Feng X, Su Z, Hu C. *Chem.-Eur. J.* 2008; 14:10896–10899. f) Pawar VD, Bettigeri S, Weng S-S, Kao J-Q, Chen C-T. *J. Am. Chem. Soc.* 2006; 128:6308–6309. [PubMed: 16683782] g) Nesterov V, Kolodiazny OI. *Russ. J. Gen. Chem.* 2005; 75:1161–1162. h) Skropeta D, Schmidt RR. *Tetrahedron: Asymmetry*. 2003; 14:265–723. i) Rowe BJ, Spilling CD. *Tetrahedron: Asymmetry*. 2001; 12:170–1708. j) Cermak DM, Du Y, Wiemer DF. *J. Org. Chem.*

- 1999; 64:388–393. k) Pogatchnik DM, Wiemer DF. *Tetrahedron Lett.* 1997; 38:3495–3498. l) Meier C, Laux WHG. *Tetrahedron: Asymmetry.* 1996; 7:89–94. m) Arai T, Bougauchi M, Sasai H, Shibasaki M. *J. Org. Chem.* 1996; 61:2926–2927. [PubMed: 11667145]
- [8]. a) Samanta S, Zhao C-G. *J. Am. Chem. Soc.* 2006; 128:7442–7443. [PubMed: 16756289] b) Dodda R, Zhao C-G. *Org. Lett.* 2006; 8:4911–4914. [PubMed: 17020334] c) Mandal T, Samanta S, Zhao C-G. *Org. Lett.* 2007; 9:943–945. [PubMed: 17284048] d) Samanta S, Perera S, Zhao C-G. *J. Org. Chem.* 2010; 75:1101–1106. [PubMed: 20085234]
- [9]. For recent examples of asymmetric synthesis on the basis of organocatalyzed cross aldol reactions, see: a) Jiang J, Chen X, Wang J, Hui Y, Liu X, Lin L, Feng X. *Org. Biomol. Chem.* 2009; 7:4355–4357. [PubMed: 19830282] b) Liu J, Yang ZG, Wang Z, Wang F, Chen XH, Liu XH, Feng XM, Su ZS, Hu CW. *J. Am. Chem. Soc.* 2008; 130:5654–5655. [PubMed: 18380434]
- [10]. The attempted cross aldol reaction of propanal and benzoylphosphonate failed, see: Samanta S, Krause J, Mandal T, Zhao C-G. *Org. Lett.* 2007; 9:2745–2748. [PubMed: 17559222]
- [11]. The synthesis of racemic β -formyl- α -hydroxyphosphonates has not been systemically studied; for examples, see: a) Haeltersa J-P, Couthon-Gourvès H, Le Goffa A, Simona G, Corbela B, Jaffrè P-A. *Tetrahedron.* 2008; 64:6537–6543. b) Guanti G, Zannetti MT, Banfi L, Riva R. *Adv. Syn. Catal.* 2001; 343:682–691.
- [12]. For an example of enzymatic resolution of secondary β -formyl- α -hydroxyphosphonates, see reference 11b.
- [13]. Acetaldehyde has been seldom used in organocatalyzed cross aldol reactions, for examples, see: a) Hayashi Y, Itoh T, Aratake S, Ishikawa H. *Angew. Chem.* 2008; 120:2112–2114. *Angew. Chem. Int. Ed.* 2008; 47:2082–2084. b) Hayashi Y, Samanta S, Itoh T, Ishikawa H. *Org. Lett.* 2008; 10:5581–5583. [PubMed: 19053723] For examples of cross aldol reactions with isatins, see: c) Chen W-B, Du X-L, Cun L-F, Zhang X-M, Yuan W-C. *Tetrahedron.* 2010; 66:1441–1446. d) Itoh T, Ishikawa H, Hayashi Y. *Org. Lett.* 2009; 11:3854–3857. [PubMed: 19655732] e) Hara N, Nakamura S, Shibata N, Toru T. *Chem. Eur. J.* 2009; 15:6790–6793. For application of acetaldehyde in other organocatalyzed reactions, see: f) Yang JW, Chandler C, Stadler M, Kampen D, List B. *Nature.* 2008; 452:453–455. [PubMed: 18288105] g) García-García P, Ladépêche A, Halder R, List B. *Angew. Chem.* 2008; 120:4797–4799. *Angew. Chem. Int. Ed.* 2008; 47:4719–4721. h) Hayashi Y, Itoh T, Ohkubo M, Ishikawa H. *Angew. Chem.* 2008; 120:4800–4802. *Angew. Chem. Int. Ed.* 2008; 47:4722–4724. i) Hayashi Y, Okano T, Itoh T, Urushima T, Ishikawa H, Uchimar T. *Angew. Chem.* 2008; 120:9193–9198. *Angew. Chem. Int. Ed.* 2008; 47:9053–9058. j) Kano T, Yamaguchi Y, Maruoka K. *Angew. Chem.* 2009; 121:1870–1872. *Angew. Chem. Int. Ed.* 2009; 48:1838–1840. k) Chandler C, Galzerano P, Michrowska A, List B. *Angew. Chem.* 2009; 121:2012–2014. *Angew. Chem. Int. Ed.* 2009; 48:1978–1980. For a review, see: l) Alcaide B, Almendros P. *Angew. Chem.* 2008; 120:4710–4712. *Angew. Chem. Int. Ed.* 2008; 47:4632–4634.
- [14]. For selected examples of primary amine-catalyzed enantioselective reactions involving an enamine or iminium intermediate, see: a) Zhou J, Wakchaure V, Kraft P, List B. *Angew. Chem.* 2008; 120:7768–7771. *Angew. Chem. Int. Ed.* 2008; 47:7656–7658. b) Martin NJA, List B. *J. Am. Chem. Soc.* 2006; 128:13368–13369. [PubMed: 17031944] c) Lu X, Liu Y, Sun B, Cindric B, Deng L. *J. Am. Chem. Soc.* 2008; 130:8134–8135. [PubMed: 18529055] d) Wang X, Reisinger CM, List B. *J. Am. Chem. Soc.* 2008; 130:6070–6071. [PubMed: 18422314] e) McCooey SH, Connon SJ. *Org. Lett.* 2007; 9:599–602. [PubMed: 17243708] f) Liu T-Y, Cui H-L, Zhang Y, Jiang K, Du W, He Z-Q, Chen Y-C. *Org. Lett.* 2007; 9:3671–3674. [PubMed: 17691800] g) Zheng B-L, Liu Q-Z, Guo C-S, Wang X-L, He L. *Org. Biomol. Chem.* 2007; 5:2913–2915. [PubMed: 17728855] h) Reisinger CM, Wang X, List B. *Angew. Chem.* 2008; 120:8232–8235. *Angew. Chem. Int. Ed.* 2008; 47:8112–8115. i) Bartoli G, Melchiorre P. *Synlett.* 2008:1759–1772. j) Chen Y-C. *Synlett.* 2008:1919–1930. k) Gogoi S, Zhao C-G, Ding D. *Org. Lett.* 2009; 11:2249–2252. [PubMed: 19415906] l) Mandal T, Zhao C-G. *Angew. Chem.* 2008; 120:7828–7831. *Angew. Chem. Int. Ed.* 2008; 47:7714–7717. m) Xie J-W, Chen W, Li R, Zeng M, Du W, Yue L, Chen Y-C, Wu Y, Zhu J, Deng J-G. *Angew. Chem.* 2007; 119:393–396. *Angew. Chem. Int. Ed.* 2007; 46:389–392. n) Huang H, Jacobsen EN. *J. Am. Chem. Soc.* 2006; 128:7170–7171. [PubMed: 16734464] For a review on primary amine catalysis, see: o) Peng F, Shao Z. *J. Mol. Catal. A.* 2008; 285:1–13. For a review on cinchona alkaloid catalysis, see: p) Song CE. *Cinchona Alkaloids in Synthesis and Catalysis.* 2009 Wiley-VCH Weinheim

- [15]. Jin D, Fan J, Wang L, Thomson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B. *Cancer Res.* 2010; 70:2245–2255. [PubMed: 20179192]
- [16]. CCDC no. 820954 contains the supplementary crystallographic data for **12**. These data can be obtained free of charge from the Cambridge Crystallographic Data centre via www.ccdc.cam.ac.uk/data_request/cif. For the ORTEP drawing of compound **12**, please see Supporting Information.

Figure 1.
Proposed favoured Transition States for the Aldol Reactions of α -Ketophosphonate with Acetone and Propanal

Figure 2.
Catalysts Screened for the Cross Aldol Reaction

Figure 3.
Synthesis of 2,4-dinitrophenylhydrazone derivative **12**

Figure 4.
Proposed transition states for the formation of the major enantiomer (A^- = 4-methoxybenzoate)

Figure 5.

Inhibitory effect of the screened compounds on cell proliferation. [The results were expressed as percentage of the control (DMSO controls set at 100%). Data are given as means $\pm$ SEM, *, $p < 0.05$ (Student's t-test)]¹⁵ (II-SP-72 is **11h**; I-VKN-81 is compound **11a**; I-VKN-97 is compound **11f**)

Figure 6.
Structure of I-ZCG-1

Table 1

Catalyst Screening and Reaction Condition Optimizations^[a]

Entry	Catalyst	Additive	Solvent	Yield (%) ^[b]	ee (%) ^[c]
1	1	none	CH ₂ Cl ₂	50	9
2	2	none	CH ₂ Cl ₂	59	13
3	3	PhCO ₂ H ^[d]	CH ₂ Cl ₂	11	3
4	4	PhCO ₂ H ^[d]	CH ₂ Cl ₂	9	10
5	5	none	CH ₂ Cl ₂	0	-
6	6	PhCO ₂ H ^[e]	CH ₂ Cl ₂	49	6
7	7	PhCO ₂ H	CH ₂ Cl ₂	45	17
8	8	PhCO ₂ H	CH ₂ Cl ₂	46	57 ^[ff]
9	8	CH ₃ CO ₂ H	CH ₂ Cl ₂	30	71 ^[ff]
10	8	EtCO ₂ H	CH ₂ Cl ₂	39	74 ^[ff]
11	8	CF ₃ CO ₂ H	CH ₂ Cl ₂	23	41 ^[ff]
12	8	<i>p</i> -TsOH	CH ₂ Cl ₂	0	-
13	8	MBA ^[g]	CH ₂ Cl ₂	46	75 ^[ff]
14	8	MBA ^[g]	THF	51	86 ^[ff]
15	8	MBA ^[g]	CH ₃ CN	38	77 ^[ff]
16	8	MBA ^[g]	hexane	45	84 ^[ff]
17	8	MBA ^[g]	benzene	53	83 ^[ff]
18	8	MBA ^[g]	toluene	53	91 ^[ff]
19 ^[g]	8	MBA ^[g]	toluene	75	93 ^[ff]

- [a]* Unless otherwise specified, all reactions were carried out with **10a** (0.30 mmol) and **9a** (1.5 mmol) in the specified solvent (2.0 mL) with the amine catalyst (10 mol %) and the acid cocatalyst (30 mol %) at rt for 7 days.
- [b]* Yield of isolated product after column chromatography.
- [c]* Determined by HPLC analysis on a ChiralCel OJ-H column.
- [d]* The loading of the acid cocatalyst was 10 mol %.
- [e]* The loading of the acid cocatalyst was 20 mol %.
- [f]* The opposite enantiomer was obtained.
- [g]* 4-Methoxybenzoic acid.
- [h]* Carried out at 0 °C.

Table 2

Enantioselective Synthesis of β -Formyl- α -hydroxyphosphonates ^[a]

En-try	R ¹	R ²	R ³	t (d)	Yield (%)	ee (%)	[c]
1	H	Ph	Me	8	11b /67	96	
2	H	Ph	Et	7	11a /75	93	
3	H	Ph	i-Pr	5	11c /67	96	
4	H	4-FC ₆ H ₄	Et	7	11d /61	99	
5	H	4-ClC ₆ H ₄	Et	7	11e /62	94	
6	H	4-BrC ₆ H ₄	Et	7	11f /55	>99	
7	H	4-IC ₆ H ₄	Et	7	11g /54	95	[d]
8	H	4-MeC ₆ H ₄	Et	6	11h /67	96	
9	H	4-MeOC ₆ H ₄	Et	7	11i /66	92	[d]
10	H	2-ClC ₆ H ₄	Et	5	11j /35	96	
11	H	3-ClC ₆ H ₄	Et	7	11k /67	93	[d]
12	H	3-ClC ₆ H ₄	Me	7	11l /60	97	
13	Me	Ph	Et	9	11m /44	68	[e][f]

^[a] All reactions were carried out with α -ketophosphonate **10** (0.30 mmol) and aldehyde **9** (1.50 mmol) in dry toluene (2.0 mL) with catalyst **8** (0.03 mmol, 10 mol %) and 4-methoxybenzoic acid (0.09 mmol, 30 mol %) at 0 °C.

^[b] Yield of isolated product after column chromatography.

^[c] Unless otherwise specified, ee values were determined by chiral HPLC analyses on a ChiralCel OJ-H column.

^[d] Determined by chiral HPLC analyses on a ChiralPak AD-H column.

^[e] Value of the major diastereomer. The ee value of the minor enantiomer was 73%.

^[f] The dr was 7:5 (¹H NMR analysis of the crude product); the Me and OH groups have *anti* configuration in the major diastereomer as determined by NOE experiments.